|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Extrahepatic complications to cirrhosis and portal hypertension: Haemodynamic and homeostatic aspects显示文摘In addition to complications relating to the liver, patients with cirrhosis and portal hypertension develop extrahepatic functional disturbances of multiple organ systems. This can be considered a multiple organ failure that involves the heart, lungs, kidneys, the immune systems, and other organ systems. Progressive fibrosis of the liver and subsequent metabolic impairment leads to a systemic and splanchnic arteriolar vasodilatation. This affects both the haemodynamic and functional homeostasis of many organs and largely determines the course of the disease. With the progression of the disease, the circulation becomes hyperdynamic with cardiac, pulmonary as well as renal consequences for dysfunction and reduced survival. Infections and a changed cardiac function known as cirrhotic cardiomyopathy may be involved in further aggravation of other complications such as renal failure precipitatingthe hepatorenal syndrome.Patients with end-stage liver disease and related complications as for example the hepatopulmonary syndrome can only radically be treated by liver transplantation.As a bridge to this treatment,knowledge on the mechanisms of the pathophysiology of complications is essential for the choice of vasoactive drugs,antibiotics,drugs with specific effects on fibrogenesis and inflammation,and drugs that target specific receptors. | S?ren M?ller Jens H Henriksen Flemming Bendtsen | 2014 | World Journal of Gastroenterology2014，20，42： | 14 |
| 2 | Pharmacological approach to acute pancreatitis显示文摘The aim of the present review is to summarize the current knowledge regarding pharmacological prevention and treatment of acute pancreatitis (AP) based on experimental animal models and clinical trials. Somatostatin (SS) and octreotide inhibit the exocrine production of pancreatic enzymes and may be useful as prophylaxis against Post Endoscopic retrograde cholangiopancreatography Pancreatitis (PEP). The protease inhibitor Gabexate mesilate (GM) is used routinely as treatment to AP in some countries, but randomized clinical trials and a meta-analysis do not support this practice. Nitroglycerin (NGL) is a nitrogen oxide (NO) donor, which relaxes the sphincter of Oddi. Studies show conflicting results when applied prior to ERCP and a large multicenter randomized study is warranted. Steroids administered as prophylaxis against PEP has been validated without effect in several randomized trials. The non-steroidal anti-inflammatory drugs (NSAID) indomethacin and diclofenac have in randomized studies showed potential as prophylaxis against PEP. Interleukin 10 (IL-10) is a cytokine with anti-inflammatory properties but two trials testing IL-10 as prophylaxis to PEP have returned conflicting results. Antibodies against tumor necrosis factor-alpha (TNF-α) have a potential as rescue therapy but no clinical trials are currently being conducted. The antibiotics beta- lactams and quinolones reduce mortality when necrosis is present in pancreas and may also reduce incidence of infected necrosis. Evidence based pharmacological treatment of AP is limited and studies on the effect of potent anti-inflammatory drugs are warranted. | Ulrich Christian Bang Synne Semb Camilla Nφjgaard Flemming Bendtsen | 2008 | World Journal of Gastroenterology2008，14，19： | 10 |
| 3 | Systematic review of the prevalence and development of osteoporosis or low bone mineral density and its risk factors in patients with inflammatory bowel disease显示文摘BACKGROUND The inflammatory bowel diseases(IBD),Crohn’s disease(CD)and ulcerative colitis(UC)are chronic,immune-mediated disorders of the digestive tract.IBD is considered to be a risk factor for developing osteoporosis;however current literature on this matter is inconsistent.AIM To assess prevalence and development of osteoporosis and low bone mineral density(BMD),and its risk factors,in IBD patients.METHODS Systematic review of population-based studies.Studies were identified by electronic(January 2018)and manual searches(May 2018).Databases searched included EMBASE and PubMed and abstracts from 2014-2018 presented at the United European Gastroenterology Week,the European Crohn’s and Colitis Organisation congress,and Digestive Disease Week were screened.Studies were eligible for inclusion if they investigated either the prevalence of osteoporosis or osteopenia and/or risk factors for osteoporosis or low BMD in IBD patients.Studies on children under the age of 18 were excluded.Only population-based studies were included.All risk factors for osteoporosis and low BMD investigated in any included article were considered.Study quality and the possibility of bias were analysed using the Newcastle-Ottawa scale.RESULTS Twelve studies including 3661 IBD patients and 12789 healthy controls were included.Prevalence of osteoporosis varied between 4%-9%in studies including both CD and UC patients;2%-9% in studies including UC patients, and 7%-15% instudies including CD patients. Among healthy controls, prevalence ofosteoporosis was 3% and 10% in two studies. CD diagnosis, lower body massindex (BMI), and lower body weight were risk factors associated withosteoporosis or low BMD. Findings regarding gender showed inconsistent results.CD patients had an increased risk for osteoporosis or low BMD over time, whileUC patients did not. Increased age was associated with decreased BMD, and therewas a positive association between weight and BMI and BMD over time. Greatheterogeneity was found in the included studies in terms of study methodologies,definitions and the assessment of osteoporosis, and only a small number ofpopulation-based studies was available.CONCLUSIONThis systematic review found a possible increase of prevalence of osteoporosis inCD cohorts when compared to UC and cohorts including both disease types.Lower weight and lower BMI were predictors of osteoporosis or low BMD in IBDpatients. The results varied considerably between studies. | Sofia Kärnsund Bobby Lo Flemming Bendtsen Jakob Holm Johan Burisch | 2020 | World Journal of Gastroenterology2020，26，35： | 8 |
| 4 | Mortality, Cancer, and Comorbidities Associated with Chronic Pancreatitis—a Danish Nationwide Matched-Cohort Study显示文摘 | Ulrich Christian Bang Thomas Benfield Lars Hyldstrup Flemming Bendtsen Jens-Erik Beck Jensen | 2013 | Gastroenterology2013，，： | 3 |
| 5 | 丹麦区域供热:百年经验显示文摘在发明新的能源技术方面丹麦拥有百年的经验,因此丹麦在国际能源市场上拥有很重要的一席之地.通过多年持续不断的创新与努力,丹麦现在可以提供环境友好并且具有成本优势的能源技术.欢迎中华人民共和国与我国在能源领域展开进一步的国际合作. | Bendt Bendtsen 刘旖祺 | 2005 | 区域供热2005，，4： | 2 |
| 6 | Safety and efficacy of Profermin~to induce remission in ulcerative colitis显示文摘AIM:To test the efficacy and safety of Profermin in inducing remission in patients with active ulcerative colitis(UC).METHODS:The study included 39 patients with mild to moderate UC defined as a Simple Clinical Colitis Activity Index(SCCAI)>4 and<12(median:7.5),who were treated open-label with Profermintwice daily for 24 wk.Daily SCCAI was reported observer blinded via the Internet.RESULTS:In an intention to treat(ITT)analysis,the mean reduction in SCCAI score was 56.5%.Of the 39 patients,24(62%)reached the primary endpoint,which was proportion of patients with≥50%reduction in SCCAI.Our secondary endpoint,the proportion of patients in remission defined as SCCAI≤2.5,was in ITT analysis reached in 18 of the 39 patients(46%).In a repeated-measure regression analysis,the estimated mean reduction in score was 5.0 points(95%CI:4.1-5.9,P<0.001)and the estimated mean time taken to obtain half the reduction in score was 28 d(95%CI:26-30).There were no serious adverse events(AEs)or withdrawals due to AEs.Profermin was generally well tolerated.CONCLUSION:Profermin is safe and may be effective in inducing remission of active UC. | Aleksander Krag Hans Israelsen Bjrn von Ryberg Klaus K Andersen Flemming Bendtsen | 2012 | World Journal of Gastroenterology2012，18，15： | 2 |
| 7 | Improved Prediction of Signal Peptides: SignalP 3.0显示文摘 | Jannick Dyrl?v Bendtsen Henrik Nielsen Gunnar von Heijne S?ren Brunak | 2004 | Journal of Molecular Biology2004，，4： | 2 |
| 8 | No difference in portal and hepatic venous bacterial DNA in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt insertion显示文摘 | Christian Mortensen Stine Karlsen Henning Gr?nb?k Dennis T. Nielsen Susanne Frevert Jens O. Clemmesen S?ren M?ller J?rgen S. Jensen Flemming Bendtsen | 2013 | Liver Int2013，，9： | 2 |
| 9 | NetAcet: prediction of Nterminal acetylation sites显示文摘 | KIEMER L BENDTSEN JD BLOM N | 2005 | Bioinformatics2005，21，7： | 1 |
| 10 | Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancer显示文摘 | P David Mozley Claus Bendtsen Binsheng Zhao | 2012 | Translational Ontology2012，5，1： | 1 |
| 11 | Detem inants of the renin-ang inlens in-aklosteronesystem in cinhosis with special enphasison the central blood volume 显示文摘 | Molier S Bendtsen F H enriksen JH | 2006 | Scand J of Gastroenterol2006，41，4： | 1 |
| 12 | The Risk of Fractures Among Patients with Cirrhosis or Chronic Pancreatitis显示文摘 | Ulrich Christian Bang Thomas Benfield Flemming Bendtsen Lars Hyldstrup Jens-Erik Beck Jensen | 2013 | Clinical Gastroenterology and Hepatology2013，，： | 1 |
| 13 | Management of cirrhotic ascites 显示文摘 | Pedersen JS Bendtsen F Moiler S | 2015 | Ther Adv Chronic Dis2015，6，3： | 1 |
| 14 | Tension-type headache: the most common, but also the most neglected, headache disorder 显示文摘 | Lars Bendtsen and Rigmor Jensen | 2006 | Current Opinion in Neurology2006，19，3： | 1 |
| 15 | EFNS guideline on the treatment of tension-type headache- report of an EFNS task force 显示文摘 | Bendtsen L Evers S Linde M | 2010 | Eur J Neurol2010，17，11： | 1 |
| 16 | Chemometric analysis of a detailed chemical reaction mechanism for meth- ane oxidation显示文摘 | Bendtsen A B Glarborg P Dam-Johansen K | 1998 | Chemometr Intell Lab1998，44，1： | 1 |
| 17 | Final results of a long-term, clinical follow-up in fatty liver patients显示文摘 | Sanne Dam-Larsen Ulrik Becker Maria-Benedicte Franzmann Klaus Larsen Per Christoffersen Flemming Bendtsen | 2009 | Scandinavian Journal of Gastroenterology2009，，10： | 1 |
| 18 | Measuring micro-fibrillar angles using light microscopy 显示文摘 | JOHN F S BENDTSEN B A | 1980 | Wood Sci1980，17，4： | 1 |
| 19 | Treatment of acute variceal bleeding 显示文摘 | Bendtsen F Krag A Moiler S | 2008 | Dig Liver Dis2008，40，5： | 1 |
| 20 | Non-classical protein secretion in bacteria 显示文摘 | Bendtsen J D Kiemer L FausbOll A | 2005 | BMC Microbiology2005，5，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员